Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab for Atopic Dermatitis
NCT00146003Phase 2Completed
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Mar 2005
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of efalizumab in atopic dermatitis (AD), sponsored by University of Medicine and Dentistry of New Jersey. Started Mar 2005; status: completed.
02
Drugs
efalizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00146003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146003.